357 related articles for article (PubMed ID: 38172980)
1. Glutamine addiction in tumor cell: oncogene regulation and clinical treatment.
Li X; Peng X; Li Y; Wei S; He G; Liu J; Li X; Yang S; Li D; Lin W; Fang J; Yang L; Li H
Cell Commun Signal; 2024 Jan; 22(1):12. PubMed ID: 38172980
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming of glutamine involved in tumorigenesis, multidrug resistance and tumor immunity.
Xiao-Yan W; Xiao-Xia Y; Peng-Fei S; Zong-Xue Z; Xiu-Li G
Eur J Pharmacol; 2023 Feb; 940():175323. PubMed ID: 36535492
[TBL] [Abstract][Full Text] [Related]
3. Loss of Heterozygosity for
Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
[TBL] [Abstract][Full Text] [Related]
4. Glutaminolysis: A Hallmark of Cancer Metabolism.
Yang L; Venneti S; Nagrath D
Annu Rev Biomed Eng; 2017 Jun; 19():163-194. PubMed ID: 28301735
[TBL] [Abstract][Full Text] [Related]
5. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.
Ni R; Li Z; Li L; Peng D; Ming Y; Li L; Liu Y
Front Oncol; 2023; 13():1143798. PubMed ID: 36959802
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.
Fogal V; Babic I; Chao Y; Pastorino S; Mukthavaram R; Jiang P; Cho YJ; Pingle SC; Crawford JR; Piccioni DE; Kesari S
Oncotarget; 2015 Jan; 6(2):1157-70. PubMed ID: 25528767
[TBL] [Abstract][Full Text] [Related]
7. Glutamine metabolism in breast cancer and possible therapeutic targets.
Li S; Zeng H; Fan J; Wang F; Xu C; Li Y; Tu J; Nephew KP; Long X
Biochem Pharmacol; 2023 Apr; 210():115464. PubMed ID: 36849062
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell metabolism: an integral view.
Romero-Garcia S; Lopez-Gonzalez JS; Báez-Viveros JL; Aguilar-Cazares D; Prado-Garcia H
Cancer Biol Ther; 2011 Dec; 12(11):939-48. PubMed ID: 22057267
[TBL] [Abstract][Full Text] [Related]
9. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.
Daye D; Wellen KE
Semin Cell Dev Biol; 2012 Jun; 23(4):362-9. PubMed ID: 22349059
[TBL] [Abstract][Full Text] [Related]
10. Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells.
Bernfeld E; Foster DA
Trends Endocrinol Metab; 2019 Jun; 30(6):357-368. PubMed ID: 31040047
[TBL] [Abstract][Full Text] [Related]
11. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
12. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.
Wise DR; DeBerardinis RJ; Mancuso A; Sayed N; Zhang XY; Pfeiffer HK; Nissim I; Daikhin E; Yudkoff M; McMahon SB; Thompson CB
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18782-7. PubMed ID: 19033189
[TBL] [Abstract][Full Text] [Related]
13. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
14. Glutamine metabolism: from proliferating cells to cardiomyocytes.
Shen Y; Zhang Y; Li W; Chen K; Xiang M; Ma H
Metabolism; 2021 Aug; 121():154778. PubMed ID: 33901502
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.
Luo Z; Xu J; Sun J; Huang H; Zhang Z; Ma W; Wan Z; Liu Y; Pardeshi A; Li S
Acta Biomater; 2020 Mar; 105():239-252. PubMed ID: 31958597
[TBL] [Abstract][Full Text] [Related]
16. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice.
Zhao X; Petrashen AP; Sanders JA; Peterson AL; Sedivy JM
Aging Cell; 2019 Jun; 18(3):e12947. PubMed ID: 30909319
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [
